Literature DB >> 18542802

Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer.

Vincent Fradet1, Christiane Gaudreau, Paul Perrotte, Jean Côté, Jean-Marie Paquin.   

Abstract

Intravesical bacille Calmette-Guérin (BCG) therapy is the most effective treatment for high-risk superficial bladder cancer. Severe systemic complications are rare, but may occur in approximately 1% of cases. We report a severe complication of intravesical BCG: a disseminated Mycobacterium bovis infection with biopsy-proven granulomatous hepatitis in a patient with bladder cancer. We also elaborate on the different management alternatives.

Entities:  

Year:  2007        PMID： 18542802      PMCID： PMC2422975          DOI： 10.5489/cuaj.83

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  22 in total

1.  [Evaluation of tolerance to endovesical BCG treatment in France: analysis of severe adverse effects notified in 3 years].

Authors:  H Debois; E Loupi; P Saliou; H Blangy; D Loeuille; P Gillet
Journal:  Prog Urol       Date:  2001-06       Impact factor: 0.915

2.  Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer.

Authors:  F Saint; J Irani; J J Patard; L Salomon; A Hoznek; S Zammattio; H Debois; C C Abbou; D K Chopin
Journal:  Urology       Date:  2001-05       Impact factor: 2.649

Review 3.  Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.

Authors:  M Elkabani; J N Greene; A L Vincent; S VanHook; R L Sandin
Journal:  Cancer Control       Date:  2000 Sep-Oct       Impact factor: 3.302

4.  Skin abscess after intravesical instillation of bacillus Calmette-Guerin for prophylactic treatment of transitional cell carcinoma.

Authors:  B Mangiarotti; A Trinchieri; R Marconato; E Pisani
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450

5.  Pathologic findings for bacille Calmette-Guérin infections in immunocompetent and immunocompromised patients.

Authors:  L A al-Bhlal
Journal:  Am J Clin Pathol       Date:  2000-05       Impact factor: 2.493

6.  Sensitivity of BCG to modern antibiotics.

Authors:  C Durek; S Rüsch-Gerdes; D Jocham; A Böhle
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

7.  Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy.

Authors:  I S Aljada; J K Crane; N Corriere; D G Wagle; D Amsterdam
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

Review 8.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Authors:  D L Lamm
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

9.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.

Authors:  D L Lamm; V D Stogdill; B J Stogdill; R G Crispen
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450
View more
  5 in total

1.  Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy.

Authors:  Vasiliki Delimpoura; Konstantinos Samitas; Ioannis Vamvakaris; Eleftherios Zervas; Mina Gaga
Journal:  BMJ Case Rep       Date:  2013-10-10

2.  Multi-organ failure with atypical liver granulomas following intravesical Bacillus Calmette-Guerin instillation.

Authors:  Michail Kaklamanos; Georgia Hardavella; Rodoula Trigidou; Georgios Dionellis; Nikolaos Paissios; Nikolaos Koulouris; Constantin Goritsas
Journal:  World J Hepatol       Date:  2011-03-27

3.  Complications of intravesical bacillus calmette-guérin.

Authors:  Liam C Macleod; Tin C Ngo; Mark L Gonzalgo
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

Review 4.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

5.  Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer.

Authors:  Mohsen Ayati; Mohammad Reza Nowroozi; Afshin Mortazavi; Solmaz Ohadian Moghadam; Hossein Ghorani
Journal:  Urol Case Rep       Date:  2017-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.